Q-omics provides the consensus-scored CCDC89 profile across patient tissues and cancer cell-line models. CCDC89 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC89 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CCDC89 RNA expression shows 15,765 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where CCDC89 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC89 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC89 survival associations across molecular data types. CCDC89 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC89 RNA expression–survival associations across cancer types. High CCDC89 expression shows unfavorable associations in LGG, BRCA, KIRP and STAD, but favorable associations in KIRC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC89 RNA expression.
This table summarizes CCDC89 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC89. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC89 shows lower tumor expression in KICH, BLCA, LUAD, LUSC and THCA and higher tumor expression in KIRC. The KIRC box plot shows higher CCDC89 RNA expression in tumor versus normal tissue (log2 FC = +0.965, t-test p < 0.001).
This table shows molecular features associated with CCDC89 in patient tissues and cancer cell lines. In patient samples, CCDC89 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC89 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and CNS.
